psp-tau-conformation-pet-imaging-correlations

Tau Conformation, Distribution, and PET Imaging Correlations in Progressive Supranuclear Palsy

Overview

Recent advances in cryo-electron microscopy (cryo-EM) have enabled the classification of tauopathies at near-atomic resolution, revealing disease-specific tau filament conformations that distinguish PSP from other 4R tauopathies and from Alzheimer's disease [@dong2026]. These microstructural differences influence intracellular localization, intercellular propagation, spatial distribution, and critically, the microscopic binding profiles and macroscopic imaging signatures of tau positron emission tomography (PET) tracers.

This page bridges neuropathological insights with in vivo PET findings, focusing on how tau filament structure determines what tau PET tracers "see" in PSP brains and what those signals reveal about disease biology.

Tau Filament Architecture in PSP

The PSP-Specific Tau Fold

Cryo-EM studies have resolved the atomic structure of tau filaments from PSP brains, revealing a unique fold pattern:

Tau Conformation, Distribution, and PET Imaging Correlations in Progressive Supranuclear Palsy

Overview

Recent advances in cryo-electron microscopy (cryo-EM) have enabled the classification of tauopathies at near-atomic resolution, revealing disease-specific tau filament conformations that distinguish PSP from other 4R tauopathies and from Alzheimer's disease [@dong2026]. These microstructural differences influence intracellular localization, intercellular propagation, spatial distribution, and critically, the microscopic binding profiles and macroscopic imaging signatures of tau positron emission tomography (PET) tracers.

This page bridges neuropathological insights with in vivo PET findings, focusing on how tau filament structure determines what tau PET tracers "see" in PSP brains and what those signals reveal about disease biology.

Tau Filament Architecture in PSP

The PSP-Specific Tau Fold

Cryo-EM studies have resolved the atomic structure of tau filaments from PSP brains, revealing a unique fold pattern:

• 4R tau only: PSP filaments consist exclusively of 4-repeat tau isoforms (no 3R admixture), consistent with the selective neuronal vulnerability pattern
• Straight filaments (SFs): PSP predominantly contains straight filaments, contrasting with AD which shows mixed paired helical filaments (PHFs) and SFs
• Distinct C-shaped fold: The PSP tau fold adopts a C-shaped conformation distinct from the folds seen in CBD, AGD, and AD
• Inter-disease specificity: Each tauopathy has a unique fold pattern — PSP filaments differ from CBD (crescent-shaped fold), AGD (arrowhead pattern), and AD (bi-lobed PHF fold)

Structural Basis for PET Tracer Binding

The tau filament fold determines PET tracer access and binding:

| Structural Feature | PET Tracer Implication |
|---|---|
| Fold geometry | Determines tracer access to binding sites |
| Cavity structure | Specific pockets accommodate tracer molecules |
| Surface charge | Influences electrostatic interactions |
| Conformational flexibility | Affects tracer on/off kinetics |
| Polymorphism | Multiple fold variants may explain PET signal heterogeneity |

Tau Filament Polymorphism within PSP

Emerging evidence suggests PSP may contain multiple tau filament variants:

• Subtype diversity: Different PSP phenotypes (Richardson syndrome, PSP-P, PSP-PAGF) may associate with different filament variants
• Regional variation: Filament structure may differ between brain regions (brainstem vs cortical)
• Clinical correlates: Filament variant may influence clinical phenotype expression

Tau PET Tracers in PSP

First-Generation Tracers (F-AV-1451/Flortaucipir)

The most extensively studied tracer in PSP:

Binding characteristics:

• High affinity for PSP tau filaments
• Predominant binding in basal ganglia, brainstem, and diencephalon
• Lower cortical binding than in AD, consistent with the PSP neuroanatomical distribution

• Globus pallidus: Highest signal — marker of PSP diagnosis
• Subthalamic nucleus: Strong signal
• Midbrain/pretectal area: Characteristic pattern
• Caudate nucleus: Moderate signal
• Thalamus: Moderate signal
• Cerebral cortex: Lower signal (differentiates from AD)

• Tau PET burden correlates with clinical severity scores
• Regional binding patterns correlate with specific clinical features
• Progressive increases over disease duration

Second-Generation 4R-Selective Tracers

Newer tracers specifically designed for 4R tauopathies:

PI-2620:

• Higher affinity for 4R tau filaments vs first-generation tracers
• Distinct binding pattern in subthalamic nucleus
• Promising for PSP differential diagnosis
• Clinical trial data (NCT05641688, NCT05456503)

• 4R tau-selective binding
• Clinical trial data (NCT03625128)
• Regional distribution studies in PSP

• Phase 3 clinical trials in PSP (NCT07422857)
• Higher specificity for 4R tau

Tracer Comparison in PSP

| Tracer | 4R Selectivity | Basal Ganglia Signal | Brainstem Signal | Cortical Signal |
|--------|----------------|----------------------|------------------|-----------------|
| Flortaucipir (AV-1451) | Moderate | High | High | Low-Moderate |
| PI-2620 | High | Very high | High | Low |
| PMBBD3 | High | High | High | Low |
| MK-6240 | Moderate | High | High | Moderate |

Structure-Imaging Correlation Framework

From Filament to PET Signal

The 2026 review by Dong et al. [@dong2026] proposes an integrative framework:

Tau Filament Conformation (Cryo-EM)
|
v
Intracellular Localization

• Neuronal perikarya
• Neuropil threads
• Glial inclusions (tufted astrocytes, oligodendrocytes)

• Trans-synaptic spread
• Glial cell uptake
• Extracellular release

• Basal ganglia predilection
• Brainstem vulnerability
• Cortical sparing (relative)

• Tracer access to filament binding sites
• Kinetic properties (on/off rates)
• Density of binding sites

• Regional SUVR patterns
• Signal-to-noise ratios
• Longitudinal change rates

How Filament Structure Affects PET Signal

The cryo-EM-resolved tau filament structures explain several PET imaging observations:

Clinical Applications of Tau PET in PSP

Diagnostic Utility

Tau PET provides in vivo evidence of tau pathology burden in PSP:

Differential diagnosis [@chen2024]:

• PSP vs PD: High basal ganglia signal distinguishes PSP
• PSP vs MSA: Different regional patterns (PSP basal ganglia > MSA cerebellar)
• PSP vs CBS: Different distribution (PSP more symmetric, brainstem-predominant)
• PSP vs AD: Lower cortical signal in PSP

• Basal ganglia SUVR > 1.3: High specificity for PSP
• Subthalamic nucleus signal: Sensitivity marker
• Cutoff values vary by tracer and reference region

Disease Progression Monitoring

Longitudinal tau PET studies demonstrate:

• Annual increases in basal ganglia and brainstem tau PET signal
• Rate of increase correlates with clinical progression
• Potential as surrogate endpoint for clinical trials
• Subtle cortical signal increases in advanced disease

Treatment Response Assessment

Tau PET could serve as a biomarker for disease-modifying therapies:

• Anti-tau immunotherapy: Reduction in tau PET signal would indicate target engagement
• Anti-aggregation approaches: Prevention of signal increase
• Neuroprotective strategies: Slowed signal progression
• Dosing optimization: PET endpoints for dose-finding

Research Directions

Unresolved Questions

The structure-imaging correlation in PSP still has open questions:

Emerging Approaches

• Kinetic modeling: Compartment modeling to estimate tau burden and turnover rates
• Partial volume correction: Advanced methods to account for small structure signal spillover
• Multi-tracer PET: Combining different tracers to characterize tau filament diversity
• PET-MRI fusion: Integrating tau PET with structural MRI and DTI
• Radioligand development: New tracers with higher specificity for PSP tau

Comparison with Other Tauopathies

PSP vs Alzheimer's Disease

| Feature | PSP | AD |
|---------|-----|-----|
| Primary tau isoform | 4R only | 3R + 4R |
| Filament type | Straight filaments | Paired helical + straight |
| Fold structure | C-shaped, unique | Bi-lobed PHF fold |
| Cortical PET signal | Low-Moderate | High |
| Basal ganglia PET | Very high | Low |
| Brainstem PET | High | Low |
| Hippocampal PET | Low | Very high |

PSP vs Corticobasal Degeneration

| Feature | PSP | CBD |
|---------|-----|-----|
| PET distribution | Symmetric, brainstem | Asymmetric, cortical |
| Basal ganglia signal | High, symmetric | High, asymmetric |
| Cortical signal | Low | Moderate-High |
| Tracer binding affinity | High for both | High for both |
| Phenotype correlation | Moderate | Moderate |

PSP vs Argyrophilic Grain Disease

| Feature | PSP | AGD |
|---------|-----|-----|
| Filament fold | C-shaped | Arrowhead |
| Primary location | Brainstem, basal ganglia | Limbic, cortical |
| PET signal pattern | Subthalamic nucleus | Amygdala, cortex |
| Clinical presentation | Subcortical syndrome | Dementia predominant |

Cross-References

• [PSP Tau Aggregate Morphology and Molecular Characteristics](/mechanisms/psp-tau-aggregate-morphology-molecular) — broader tau biology
• [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp) — PET imaging in atypical parkinsonism
• [Tau PET Imaging](/biomarkers/tau-pet-imaging) — general tau PET principles
• [PSP Neuropathology](/mechanisms/psp-neuropathology) — neuropathological context
• [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging) — PET for progression monitoring
• [PSP Astrocytic Pathology](/mechanisms/psp-astrocytic-pathology-tufted-astrocytes) — glial tau inclusions
• [4R-Tauopathy Brain Region Vulnerability](/mechanisms/4r-tauopathy-brain-region-vulnerability) — vulnerability patterns

References